1. Home
  2. JMM vs GRML Comparison

JMM vs GRML Comparison

Compare JMM & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Multi-Market Income Fund (MA)

JMM

Nuveen Multi-Market Income Fund (MA)

HOLD

Current Price

$5.79

Market Cap

55.8M

Sector

Finance

ML Signal

HOLD

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.29

Market Cap

51.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
JMM
GRML
Founded
1988
N/A
Country
United States
United States
Employees
N/A
5
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
55.8M
51.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
JMM
GRML
Price
$5.79
$0.29
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.7K
3.6M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
5.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.67
$0.27
52 Week High
$6.52
$0.55

Technical Indicators

Market Signals
Indicator
JMM
GRML
Relative Strength Index (RSI) 48.32 30.94
Support Level $5.77 $0.27
Resistance Level $5.90 $0.44
Average True Range (ATR) 0.06 0.04
MACD 0.01 -0.01
Stochastic Oscillator 53.13 9.64

Price Performance

Historical Comparison
JMM
GRML

About JMM Nuveen Multi-Market Income Fund (MA)

Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: